针对大脑的纳米治疗阿尔茨海默病通过调节微质极化和重塑微环境来治疗阿尔茨海默病
Han Yang1, Xiaowei Zhao1, Min Liu1
1College of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning 110016, China.
International journal of pharmaceutics
|October 20, 2025
概括
这项研究开发了一种新的药物递送系统 (ASR) 来治疗阿尔茨海默病 (AD). ASR针对并重编程炎症性微质,改善AD小鼠的认知功能.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默氏病 (AD) 是一种流行的神经退行性疾病,与由M1微质驱动的神经炎症有关.
- 向微质表型为AD提供了潜在的治疗策略.
研究的目的:
- 开发一种智能药物输送系统,能够穿越血脑屏障 (BBB) 并调节AD治疗的微质偏振.
- 将沙米特醇封装在一个经过工程修改的阿基宁-6 (ASR) 的阿波费里丁纳米中,以进行有针对性的输送.
主要方法:
- 工程化阿波费里丁 (AFn) 纳米的制造,封装salmeterol (Sal) 和表面修饰与阿尔金因-6 (R6),以创建ASR.
- 评估ASR通过转移素受体1 (TfR1) 介导的细胞转移和其由微质细胞吸收,穿越BBB的能力.
- 在体外和体内评估ASR的治疗疗效,重点关注M1微质再极化和AD小鼠模型中的认知改善.
主要成果:
- ASR成功地穿越了BBB,并被微质内化.
- 该ASR系统证明了在酸性炎症环境中对pH敏感的药物释放.
- ASR有效地促进了亲炎性M1微质的再极化到抗炎M2表型.
- 用ASR治疗在AD小鼠中显著改善了学习和认知能力.
结论:
- 工程化阿波费里丁纳米提供了一个有前途的平台,用于在BBB的向药物输送.
- 通过ASR调节微质极化代表了减轻阿尔茨海默病的可行的治疗策略.
- 这种方法为治疗以神经炎症为特征的神经退行性疾病提供了一个新的途径.
相关概念视频
Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


